Biopsy Devices Market Research Report Information By Product Type (Biopsy Guns, Biopsy Guidance System, Biopsy Needles [Vacuum-Assisted Biopsy (VAB) Devices, Fine Needle Aspiration Biopsy (FNAB) Devices, Core Needle Biopsy (CNB) Devices], Biopsy Forceps, Localization Wires, and Others), By Application (Breast Biopsy, Prostate Biopsy, Liver Biopsy, Lung Biopsy, Gynecological Biopsy, and Others), By Guidance Technique (Ultrasound-Guided Biopsy, Stereotactic Guided Biopsy, MRI-Guided Biopsy, CT Guided Biopsy, and Others), By End User (Hospital

Global Biopsy Devices Market Overview

The Biopsy Devices Market Size was valued at USD 2.64 billion in 2023 and is projected to grow from USD 2.81 billion in 2024 to USD 4.4 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.72% during the forecast period (2024 - 2032). The increasing prevalence of cancer and increasing preference for minimally invasive surgeries are driving the market growth.

  Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

In October 2023, Delfi Diagnostics, a well-financed startup in the rapidly growing area of developing blood tests for cancer detection, announced the debut of a new test called FirstLook Lung. The purpose of this test is to identify individuals who would derive the greatest advantage from lung cancer screening. This methodology introduces a novel method in the field of liquid biopsy, where DNA fragments contained in the blood are utilized for the detection and characterization of cancers. Grail, a separate firm specializing in the development of a blood test for cancer screening, has emphasized that their product is most effective when utilized for the simultaneous detection of various types of cancer. Exact Sciences and Freenome, among other companies, are now working on creating tests specifically designed to identify colorectal cancer. However, Delfi seems to be the initial platform to specifically prioritize lung cancer, which is the primary cause of cancer-related fatalities.

In August 2022, Predicine introduced PredicineCARE, a genomic profiling product for analyzing genetic information in blood and urine, which has received the CE mark and is now available in Europe. The cell free DNA (cfDNA) assay is a focused next-generation sequencing (NGS) test used to identify specific changes in the DNA sequence, such as single nucleotide variants, insertions and deletions, DNA re-arrangements, and copy number variations, in individuals who have been diagnosed with cancer. PredicineCARE focuses on 152 specific genes, which are known to be actionable and have connections to available medicines or clinical studies, according to the business. The assay has been employed in clinical trials, patient testing, and the creation of companion diagnostics. The introduction of PredicineCARE as the initial product to receive CE-IVD marking is a noteworthy achievement that supports the organization's goal of offering a cost-effective and easily obtainable molecular testing option in the European market. A team of scientists from Bristol Myers Squibb (BMS) conducted a comparative research in which they assessed five prominent circulating tumor DNA (ctDNA) NGS tests that utilize large gene panels. Each vendor received and evaluated identical blinded reference panels that mimicked clinical cell-free DNA samples. The summarized data was submitted to BMS scientists who conducted thorough and impartial analyses of the performance of each assay.

Biopsy Devices Market Trends

Rising prevalence of cancer to boost market growth

A biopsy is a type of diagnostic procedure used to find both malignant and non-cancerous abnormalities in the human body. The global market for biopsy devices is projected to expand due to the rising incidence of cancer in the population. For instance, cancer is the second-leading cause of death in the US after heart disease and is the primary cause of death in Canada. According to the American Cancer Society, there were 693,000 cancer fatalities and 1.9 million new cancer diagnoses in 2018. In North America, prostate cancer is the disease that is most frequently diagnosed in men, but breast cancer continues to be the most common cancer in women. Lung cancer continues to be the leading cause of death in both sexes. One of the main causes of the population's cancer incidences rising is the rapid change in lifestyle, as well as the intake of alcohol and cigarette products. Boston Scientific Corporation, BD, Qiagen, F. Hoffman La-Roche Ltd., Hologic, and other significant manufacturers of biopsy instruments and related products for the diagnosis of cancer and other disorders. Hence, it is anticipated that the global market for biopsy instruments will expand due to the rising incidence of cancer worldwide.

Biopsy Devices Market Product Type Insights

Biopsy Devices Product Type Insights

The Market segments of Biopsy Devices, based on product type, includes biopsy guns, biopsy guidance system, biopsy needles, biopsy forceps, localization wires, and others. The biopsy guns segment accounted for the largest share in 2022 and the biopsy needle segment is anticipated to be the fastest growing for the forecast period 2023-2030. Over the forecast period, a surge in demand for these weapons to collect samples from internal organs' soft tissues, such as kidneys, breasts, and lungs, is anticipated to support the market's overall expansion. One of the main elements supporting the segment's growth is the increasing demand for quick and delicate cell sample collection for biopsies.

Figure 2: Biopsy Devices Market, by Product Type, 2023 & 2030 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Biopsy Devices Application Insights

Based on application, the global Biopsy Devices industry has been segmented into breast biopsy, prostate biopsy, liver biopsy, lung biopsy, gynecological biopsy, and others. The breast biopsy segment accounted for the largest share in 2022 and is anticipated to be the fastest growing for the forecast period 2023-2030. This is due to the rise in breast cancer cases that has been seen over the years and is predicted to continue in the coming years. At the moment, breast cancer can be detected effectively and quickly using modern biopsy tools. The demand for the usage of biopsy equipment has increased globally due to increased public awareness of disease screening and technological advancements in biopsy devices.

May 2021 Hologic announced the launch of the Brevera Breast Biopsy System with CorLumina Imaging Technology in Japan. The system allows for real-time imaging and biopsy sample collection in a single system, reducing the need for multiple devices during the biopsy procedure.

Biopsy Devices Guidance Technique Insights

Based on guidance technique, the global market of biopsy devices has been categorized into ultrasound-guided biopsy, stereotactic guided biopsy, MRI-guided biopsy, CT guided biopsy, and others. The CT guided biopsy segment accounted for the largest share in 2022 and is anticipated to be the fastest growing for the forecast period 2023-2030. The market for ultrasound-guided biopsies is anticipated to grow at the highest CAGR during the forecast period due to the growing use of this technique for cancer detection in diagnostic laboratories as well as its many advantages and diverse applications. These advantages include high throughput, high efficiency, accuracy, and minimal invasiveness, all of which are anticipated to fuel this segment's market expansion.

Biopsy End User Insights

Based on end user, the global market biopsy devices has been categorized into hospitals & clinics, diagnostic & imaging centers, academic & research institutes, and others. The hospitals & clinics segment accounted for the largest share in 2022 and is anticipated to be the fastest growing for the forecast period 2023-2030. Due to the wide availability of cutting-edge medical equipment and reimbursement policies, the hospitals & clinics market segment controlled over 68% of the global market share for biopsy instruments. The National Average Medicare rate for breast biopsy operations with the implantation of a breast localization device in hospitals was around USD 1,400 in 2021, according to the coding and reimbursement guide from Hologic. The number of surgical procedures performed in hospitals will increase as a result of these variables, which will increase the use of biopsy medical equipment.

Biopsy Devices Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The growth of the North America Biopsy Devices market is attributed to the high market penetration rates of cutting-edge products, like vacuum-assisted biopsy systems, and a quickly rising market demand for disposable products.

Further, the major countries studied are: the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: BIOPSY DEVICES MARKET SIZE BY REGION 2023 & 2030 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

North America Biopsy Devices market accounts for the largest market share due to the presence of well-established market players in the nation, high market penetration rates of cutting-edge products, like vacuum-assisted biopsy systems, and a quickly rising market demand for disposable products. Furthermore, the US market of Biopsy Devices held the largest market share and the Canada market of Biopsy Devices accounted for the second largest market in North America. The inclination for minimally invasive procedures, an increase in cancer incidence globally, and government initiatives for diagnosis in this region are the driving forces behind the growth of the biopsy instruments market.

The Asia-Pacific Biopsy Devices Market is expected to grow at the highest rate from 2023 to 2030. This is due to the rising incidence of cancer, the big populations in nations like China and India, the improved healthcare infrastructure, increased healthcare spending and government initiatives, and the increasing attention of major market participants in the region are all contributing to the segment's rise. Moreover, the China market of Biopsy Devices held the largest market share, and the Japan market of Biopsy Devices was the fastest-growing market in the Asia-Pacific region.

Biopsy Devices Key Market Players & Competitive Insights

Many global, regional, and local vendors characterize the biopsy device market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality polyamide products to survive and succeed in an intensely competitive market.

The market vendors’ growth depends on market conditions, government support, and industry development. Thus, the vendors should focus on expanding geographically and improving services. Argon Medical Devices (US), BD (US), Cook Medical (US), CONMED Corporation (US), Olympus Corporation (Japan), Hologic, Inc. (US), Cardinal Health Inc. (US), Integra LifeSciences (US), Medtronic plc (US), Mammotome (US), INRAD (US), and Trivitron Healthcare (India) are the major companies in the market that compete in terms of availability, quality, price, and technology. They primarily focus on the development of biopsy device products. Although international players dominate the market, regional and foreign players with small market shares also have a presence. The international players may strengthen their presence worldwide through acquisitions during the forecast period.

Argon Medical Devices (US) is a global medical technology company that specializes in the development, manufacturing, and marketing of medical devices for interventional procedures. The company has a strong focus on providing innovative, high-quality products to healthcare professionals, and improving patient care. Argon Medical Devices offers a wide range of products, including vascular access devices, biopsy and drainage devices, and peripheral vascular devices.

Key Companies in the market of Biopsy Devices include

• Argon Medical Devices (US)


• BD (US)


• Cook Medical (US)


• CONMED Corporation (US)


• Olympus Corporation (Japan)


• Hologic, Inc. (US)


• Cardinal Health Inc. (US)


• Integra LifeSciences (US)


• Medtronic plc (US)


• Mammotome (US)


• INRAD (US)


• Trivitron Healthcare (India) among others

Biopsy Devices Industry Developments

March 2022 Trivitron Healthcare, a global medical technology company, has acquired a 100% stake in The Kennedy Company (US), a leading manufacturer of radiation protection X-ray shielding material and acoustic barrier products. This will help Trivitron to serve acquired companies’ clients with Breast Biopsy products in the US.

September 2021 Olympus Corporation launched EZ Shot 3 Plus 25 G needle in September 2021. The EZ Shot 3 Plus is a fine needle biopsy device that is designed to obtain high-quality tissue samples with minimal damage to surrounding tissue.

January 2020 BD acquired Straub Medical AG (Switzerland) which develops and manufactures biopsy systems. This acquisition expands BD's portfolio of breast biopsy products and strengthens its position in the market.

Biopsy Devices Market Segmentation

Biopsy Devices Product Type Outlook

• Biopsy Guns


• Biopsy Guidance System


• Biopsy Needles
  
  
  
  • Vacuum-Assisted Biopsy (VAB) Devices
  
  
  • Fine Needle Aspiration Biopsy (FNAB) Devices
  
  
  • Core Needle Biopsy (CNB) Devices
  
  
  
  


• Biopsy Forceps


• Localization Wires


• Others

Biopsy Devices Application Outlook

• Breast Biopsy


• Prostate Biopsy


• Liver Biopsy


• Lung Biopsy


• Gynecological Biopsy


• Others

Biopsy Devices Guidance Technique Outlook

• Ultrasound-Guided Biopsy


• Stereotactic Guided Biopsy


• MRI-Guided Biopsy


• CT Guided Biopsy


• Others

Biopsy Devices End User Outlook

• Hospitals & Clinics


• Diagnostic & Imaging Centers


• Academic & Research Institutes


• Others

Biopsy Devices Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America